THU0258 Oral Start: Effects of the Oral JAK Inhibitor Tofacitinib Monotherapy Versus Methotrexate on Patient-Reported Outcomes in the Phase 3 Oral Start Trial of Active Rheumatoid Arthritis

2013 ◽  
Vol 72 (Suppl 3) ◽  
pp. A252.3-A253 ◽  
Author(s):  
V. Strand ◽  
R. Fleischmann ◽  
R. E. Alten ◽  
T. Koncz ◽  
S. H. Zwillich ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Patient Reported Outcomes ◽  
Active Rheumatoid Arthritis ◽  
Jak Inhibitor ◽  
Phase 3 ◽  
Patient Reported ◽  
Start Trial

scholarly journals Tofacitinib or adalimumab versus placebo: patient-reported outcomes from a phase 3 study of active rheumatoid arthritis

Rheumatology ◽  
2016 ◽  
Vol 55 (6) ◽  
pp. 1031-1041 ◽  
Author(s):  
Vibeke Strand ◽  
Ronald F. van Vollenhoven ◽  
Eun Bong Lee ◽  
Roy Fleischmann ◽  
Samuel H. Zwillich ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Patient Reported Outcomes ◽  
Active Rheumatoid Arthritis ◽  
Placebo Patient ◽  
Phase 3 ◽  
Patient Reported
Sign in / Sign up

Export Citation Format

Share Document